Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991894 · ClinicalTrials.gov registry record
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
A clinical trial of Anemia, Aplastic, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,517
- Enrollment target
- 1
- Study location
NCT06991894: Completed study of Anemia, Aplastic, sponsored by Novartis Pharmaceuticals.
NCT06991894 is a study of Anemia, Aplastic that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,517 participants, above the 38-participant average among 5 other Anemia, Aplastic trials with a reported enrollment target (6524% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06991894, a study of Anemia, Aplastic, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.
Primary Outcome
The Kaplan-Meier analysis technique was used to estimate probability. Hematologic response was defined as the first occurrence of an 8-week period without any transfusion procedure. Treatment categories included: * CSA alone * CSA + ETB * ETB alone * ATG + CSA * ATG + CSA + ETB
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,517 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2024-05-17 |
What the finished NCT06991894 record still lists
NCT06991894 is an observational study that tracks outcomes without assigning an intervention. Its 2,517 participants enrollment target places it among the larger protocols in the corpus, above the 38-participant average among 5 other Anemia, Aplastic trials with a reported enrollment target (6524% higher).
The record links to 1 condition, with Anemia, Aplastic appearing as the primary indexed condition, and to 0 interventions.
NCT06991894 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06991894 about?
NCT06991894 is a clinical study titled "Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study". The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.
What is the current status of trial NCT06991894?
This trial is currently completed. The enrollment target is 2,517 participants. The study started on 2021-07-14. Estimated completion is 2024-05-17.
What conditions does trial NCT06991894 study?
This clinical trial studies the following conditions: Anemia, Aplastic.
Who is sponsoring clinical trial NCT06991894?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991894 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia, Aplastic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
COMPLETED · Phase 2
-
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
COMPLETED · NA
-
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
COMPLETED · Phase 1
-
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI